# A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects

> **NCT05995444** · PHASE1 · COMPLETED · sponsor: **AN2 Therapeutics, Inc** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Epetraborole and matching placebo
- **DRUG:** Epetraborole
- **DRUG:** Placebo
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT05995444
- **Lead sponsor:** AN2 Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-05
- **Primary completion:** 2023-07-26
- **Final completion:** 2023-08-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05995444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05995444, "A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05995444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*